Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TET2 mutant |
| Therapy | N/A |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | not applicable |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TET2 mutant | acute myeloid leukemia | not applicable | N/A | Clinical Study | Prognostic | In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606). | 24524305 25412851 24994606 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24524305) | Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. | Full reference... |
| (25412851) | Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. | Full reference... |
| (24994606) | Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. | Full reference... |